T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapyGuido Ghilardi, Marco Ruella, Jakub Svoboda et al.|Nature Medicine|2024Cited by 254
Both CD28 ligands CD80 (B7-1) and CD86 (B7-2) activate phosphatidylinositol 3-kinase, and wortmannin reveals heterogeneity in the regulation of T cell IL-2 secretionYuji Ueda, Stephen G. Ward, Bruce L. Levine et al.|International Immunology|1995Cited by 74
Production of Human CRISPR-Engineered CAR-T CellsSangya Agarwal, Carl H. June, Nils Wellhausen et al.|Journal of Visualized Experiments|2021Cited by 19
Multiplex engineering using microRNA-mediated gene silencing in CAR T cellsGiulia Golinelli, Bruce L. Levine|Frontiers in Immunology|2025Cited by 4
Production of Human CRISPR-Engineered CAR-T CellsSangya Agarwal, Carl H. June, Nils Wellhausen et al.|Journal of Visualized Experiments|2021Cited by 2